*2.3. Mouse Models of Liver Fibrosis: What Can be Learned for Human Disease?*

In hepatology research, preclinical mouse models are still essential for analyzing complex disease-associated changes to unravel cellular reactions, signaling pathways, and networks, as well as for the preclinical testing of novel therapeutic useful anti-inflammatory or anti-fibrotic drugs [62]. The usage of mice is majorly attributable to the fact that mice are inexpensive, can be bred in large quantities on an inbred genetic background helping to establish reproducible results, and having general features in anatomy and biology that are similar to humans [62]. Nowadays, a large number of well-established injury models are commonly used in experimental and molecular hepatology. For most of these models, we have recently published standard operating protocols (SOPs) that provide information about the scientific background, treatment, duration, and burden [75–84].

In Table 1, we exclusively list relevant experimental models that have been the focus of liver-related MC research.


**Table 1.** Established mouse injury models that have been the focus of liver-related mast cell research.

Abbreviations used are: BCG: bacillus Calmette–Guérin, BDL: bile duct ligation, CCl4: carbon tetrachloride D-GalN: D-galactosamine, DEN: diethylnitrosamine, DMN: dimethylnitrosamine, h: hour(s), HCC: hepatocellular carcinoma; i.p.: intraperitoneal, LPS: lipopolysaccharide, wks: weeks.
